6505--Esomeprazole Capsules (VA-27-00001026)

The Department of Veterans Affairs National Acquisition Center seeks a single award for supply of Esomeprazole Magnesium capsules in multiple strengths and package sizes through the VA and DoD Pharmaceutical Prime Vendor Programs, with proposals due July 13, 2026.

The original due date of June 30 was extended to July 6 (amended June 25), then to July 13 (amended July 1). Offerors must acknowledge receipt of amendments or face rejection. Place of performance is Hines, Illinois (VA OPAL/National Acquisition Center, Building 37, 1st Avenue, One Block North of Cermak, Hines, Illinois 60141).

The solicitation covers six line items: Esomeprazole 20mg in 30-count and 90-count unit-of-use bottles, 20mg in 500-count or 1,000-count bulk bottles, 40mg in 30-count and 90-count unit-of-use bottles, and 40mg in 500-count or 1,000-count bulk bottles. Total estimated annual usage across all government participants is approximately 419,145 bottles. The contract includes a 60-calendar-day maximum implementation period, a one-year base ordering period, and four optional one-year extension periods. Offerors must submit pricing for the base year and all four option periods.

Government participants include all VA facilities, DoD ordering activities, Indian Health Service, Bureau of Prisons, Captain James A. Lovell Federal Health Care Center, and under Option 2, State Veterans Homes. No set-aside applies. Small business subcontracting plans are required for contractors exceeding the $900,000 threshold. Offerors must establish business-to-business agreements with current PPV contractors (McKesson for VA; McKesson, Cencora, Cardinal Health, and DMS Pharmaceutical Group for DoD), provide unique 11-digit NDC numbers, letters of commitment from manufacturers if a distributor, cGMP compliance documentation, and barcode labeling meeting GS1-128 or HIBCC standards. All offerors must comply with FDA good manufacturing practice standards, Drug Supply Chain Security Act requirements, and a 0.5% cost recovery fee embedded in quoted prices.